Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for Asthma Treatment Candidate HBM7575/SKB575
Event summary
- Harbour BioMed and Kelun-Biotech received NMPA approval for IND application of HBM7575/SKB575 to treat asthma.
- HBM7575/SKB575 is a long-acting bispecific antibody targeting TSLP and an undisclosed antigen.
- The molecule has already been dosed in Phase 1 trials for atopic dermatitis.
- Kelun-Biotech leads development and commercialization, with Harbour BioMed sharing benefits per agreement.
The big picture
The approval marks another step in the growing trend of bispecific antibody development for immune-mediated conditions. With asthma affecting 300 million people globally and current therapies falling short, HBM7575/SKB575's long-acting profile could address unmet needs if clinical success is achieved.
What we're watching
- Clinical Progress
- The pace at which HBM7575/SKB575 advances through asthma trials will determine its competitive positioning.
- Commercial Strategy
- How Kelun-Biotech executes global development and commercialization under the collaboration agreement.
- Market Differentiation
- Whether HBM7575/SKB575's dual mechanism of action can achieve broader inflammation control than single-target therapies.
Related topics